Background: In people with chronic kidney disease (CKD), HbA1c may be a problematic measure of glycemic control. Glycated albumin and fructosamine have been proposed as better markers of hyperglycemia in CKD. In the present study we investigated associations of HbA1c, glycated albumin, and fructosamine with fasting glucose by CKD categories. Methods: A cross-sectional analysis was performed of 1665 Atherosclerosis Risk in Communities Study participants with diagnosed diabetes aged ≥65 years. Spearman's rank correlations (r) were compared and Deming regression was used to obtain root mean square errors (RMSEs) for the associations across CKD categories defined using estimated glomerular filtration rate and urine albumin:creatinine ratio. Results: Correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose were lowest in people with severe CKD (HbA1c r = 0.52, RMSE = 0.91; glycated albumin r = 0.39, RMSE = 1.89; fructosamine r = 0.41, RMSE = 1.87) and very severe CKD (r = 0.48 and RMSE = 1.01 for HbA1c; r = 0.36 and RMSE = 2.14 for glycated albumin; r = 0.36 and RMSE = 2.22 for fructosamine). Associations of glycated albumin and fructosamine with HbA1c were relatively similar across CKD categories. Conclusions: In older adults with severe or very severe CKD, HbA1c, glycated albumin, and fructosamine were not highly correlated with fasting glucose. The results suggest there may be no particular advantage of glycated albumin or fructosamine over HbA1c for monitoring glycemic control in CKD.
Introduction
Chronic kidney disease (CKD) is a common condition in older adults with diabetes. 1 For a long time, HbA1c has been the standard clinical measure of glycemic control in people with diabetes regardless of CKD status: HbA1c is formed when glucose binds to the N-terminal of the β-chain of hemoglobin in erythrocytes, reflecting glycemic exposure over the past 2-3 months. The interpretation of HbA1c can be problematic when erythrocyte turnover is altered. Impaired erythrocyte turnover often presents as anemia and is common in CKD, even in early stages, 2 and thus concerns have been raised about the performance of HbA1c as a measure of glycemic control in the setting of CKD. 3 Non-traditional markers of hyperglycemia, such as glycated albumin and fructosamine, have been advocated as better measures of glycemic status than HbA1c in the setting of CKD. [4] [5] [6] Glycated albumin and fructosamine are ketoamines that are produced when glucose binds to serum albumin and indiscriminately to total serum proteins, respectively. Both markers reflect average glycemia over the past 2-3 weeks. 7 Prior studies have suggested that HbA1c underestimates hyperglycemia in advanced CKD, but most of these studies have been conducted among individuals with advanced stages of kidney disease, including dialysis patients. 5, [8] [9] [10] However, the vast majority of people with CKD will develop advanced CKD requiring renal replacement therapy and it is unclear whether HbA1c underestimates glycemia in people with early CKD. To our knowledge, no studies have conducted head-to-head comparisons of HbA1c, glycated albumin, and fructosamine with fasting glucose. Furthermore, data comparing HbA1c, glycated albumin, and fructosamine with fasting glucose in the setting of the early stages of CKD are lacking.
The objective of the present study was to evaluate whether the associations of HbA1c, glycated albumin, and fructosamine with fasting glucose varied by CKD stage and/or anemia status in people with diabetes.
Methods

Study population
A cross-sectional was conducted analysis using data from the Atherosclerosis Risk in Communities (ARIC) Study (https://www2.cscc.unc.edu/aric/, accessed 26 October 2017), 11 an ongoing prospective cohort study of men and women from four US communities (Minneapolis, Minnesota; Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi). Participants were recruited in 1987-89 (Visit 1) and had subsequent in-person visits in 1990-92 (Visit 2), 1993-95 (Visit 3), 1996-98 (Visit 4), and 2011-13 (Visit 5) . For the present analysis, we included participants who had completed the most recent visit (Visit 5). Of the 6538 participants who attended Visit 5, those without a history of diagnosed diabetes defined by self-report of physician diagnosis and no use of glucose-lowering medication (n = 4391) were excluded, as were non-White or non-Black participants (n = 4), Black participants from Minneapolis, Minnesota, and Washington County, Maryland (n = 14), those with prevalent end-stage renal disease (n = 33), missing estimated glomerular filtration rate (eGFR; n = 46), and missing albuminuria (n = 179), those using erythropoietin-stimulating hormone or iron supplementation (n = 15), those fasting for <8 h (n = 89), and those missing any of the glycemic markers (fasting glucose, HbA1c, glycated albumin, or fructosamine; n = 112). Thus, the final analytic sample was 1665 participants with diagnosed diabetes.
All study protocols were reviewed and approved by the institutional review boards at all participating institutions, and written documentation of informed consent was obtained from all participants.
Classification of CKD
In the present study, CKD categories were defined using the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 Clinical Practice Guidelines 12 using eGFR and albuminuria. The 2012 CKD Epidemiology Collaboration (CKD-EPI) equation using serum creatinine and cystatin C, age, sex, and race was used to estimate glomerular filtration rate (GFR). 13 Serum creatinine was measured on a Roche Modular P Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN, USA) using the creatinase enzymatic method and standardized to the isotope-dilution mass spectrometrytraceable reference method (see http://www2.cscc.unc. edu/aric/cohort-manuals, accessed 26 October 2017). Serum cystatin C was measured using an immunoassay turbidimetric method (Gentian, Moss, Norway), calibrated and standardized to International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) references. Albuminuria was assessed as the urinary albumin:creatinine ratio (ACR) from spot urine samples and expressed as milligram albumin per gram creatinine. Urine albumin was measured using nephelometric methods on either the Dade Behring BN100 (Deerfield, IL, USA) or the Beckman IMMAGE Nephelometer (Beckman Coulter Inc., Brea, CA, USA). Urine creatinine was measured using the Jaffe method. Estimated GFR was categorized in the following GFR categories: G1, eGFR ≥90 mL/min per 1 . Albuminuria was categorized into the following stages: A1, ACR <30 mg/g; A2, ACR 30-300 mg/g; and A3, ACR >300 mg/g. Estimated GFR and albuminuria categories were combined to define four CKD categories: no CKD (G1/G2 and A1); moderate CKD (G3a and A1; G1/G2 and A2); severe CKD (G3b and A1; G3a and A2; G1/G2 and A3); or very severe CKD (G3a and A3; G3b and A2/A3; G4/G5).
Measurement of glucose, HbA1c, glycated albumin, and fructosamine Glucose was measured from plasma using the hexokinase method, whereas HbA1c was measured in EDTAwhole blood using an automated HPLC analyzer (Tosoh G7; Tosoh Bioscience Inc., Tokyo, Japan). This instrument uses non-porous ion-exchange HPLC to accurately and precisely separate stable HbA1c (hemoglobin A with glucose bound to the N-terminus of the β-chain) from other hemoglobin components. The percentage of HbA1c is calculated by the analyzer when the separated hemoglobin components pass through the LED photometer flow cell. Glycated albumin and fructosamine were measured in serum using a Roche Modular P800 Chemistry Analyzer (Roche Diagnostics). Glycated albumin was measured using a method developed by the Asahi Kasei Pharma Corporation (Tokyo, Japan), which separately measures total albumin and glycated albumin. The interassay coefficient of variation for HbA1c was 1.9% at an HbA1c value of 5.36%-points. The interassay coefficients of variation for glycated albumin were 2.3% at a concentration of 1.579 g/ dL and 2.8% at a concentration of 0.426 g/dL. Fructosamine was measured using a colorimetric assay (Roche Diagnostics), with interassay coefficients of variation of 3.2% at a concentration of 212.6 μmol/L and 2.5% at a concentration of 856.7 μmol/L.
Measurement of other covariates
Hypertension was defined as mean systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or the current use of hypertension medication. Anemia status was defined using World Health Organization's sex-specific cut-off points of hemoglobin <13.0 g/dL for men and <12 g/dL for women.
14 Body mass index was calculated using weight and height. Diabetes duration was calculated as the time between the first report of doctor-diagnosed diabetes or selfreported use of glucose-lowering medication and Visit 5. Medication use for diabetes, hypertension, cholesterol, and anemia (erythropoietin-stimulating agents or iron supplementation) was determined by a medication inventory.
Statistical analysis
Study participant characteristics were summarized according to CKD category at baseline. Associations of HbA1c, glycated albumin, and fructosamine with fasting glucose were evaluated using Spearman's rank correlation coefficients (r), and Deming regression was used to generate regression statistics and root mean square errors (RMSEs) overall and by CKD category. Ordinary regression requires one variable to be the dependent variable, whereas in Deming regression both variables have the same status. 15, 16 When the slope is equal to 1, then the dependent variable and the independent variable are the same; otherwise, the two variables are different from each other. When the distributions of variables are different between groups, the RMSE is more relevant because Spearman's rank correlation coefficient is a function of the distribution of the explanatory variable. The RSME reflects the deviations from the regression line. A lower RMSE value suggests better fit and RMSEs that are consistent across groups indicate that linear associations between the explanatory and independent variables are similar. We graphically showed the associations between the glycemic markers using scatterplots fitted with Deming regression lines. We further stratified the CKD groups by anemia status to examine whether the associations were different by anemia status.
We conducted sensitivity analyses using CKD defined using eGFR only and albuminuria only. Glycated albumin and fructosamine may also have abnormal values in the setting of abnormal albumin metabolism. Therefore, we excluded people with low serum albumin (<3.4 mg/dL). To quantify the association of HbA1c, glycated albumin, and fructosamine with fasting glucose or HbA1c ignoring CKD status, we stratified by anemia status only. In these analyses, we defined anemia as a three-level variable: "no anemia" refers to hemoglobin values ≥13 g/dL in men and ≥12.0 g/dL in women; "mild anemia" refers to hemoglobin values 11.0-12.9 g/ dL in men and 11.0-11.9 g/dL in women; and "moderate anemia" refers to hemoglobin values <11.0 g/dL in men and women. Antidiabetic medication can alter glucose metabolism in the short and long term, so we stratified CKD categories by any or no antidiabetic medication use. We also further stratified CKD categories by race and sex to evaluate whether associations of HbA1c, glycated albumin, and fructosamine with fasting glucose differed by these factors. Postprandial hyperglycemia has been postulated to affect the correlation between fasting glucose and HbA1c by diabetes severity; 17 therefore, we also stratified HbA1c (<7%, 7-<8%, and ≥8%).
Results
In the present study population of 1665 participants with diagnosed diabetes, the prevalence of moderate, severe, and very severe CKD was 27.9%, 16.1%, and 12.6%, respectively. Older age, hypertension, obesity, duration of diabetes, and anemia were more common at more severe CKD stages ( Table 1 ). The prevalence of anemia in the no CKD and moderate, severe, and very severe CKD categories was 21.0%, 30.6%, 43.7%, and 54.6%, respectively. Median HbA1c, glycated albumin, and fructosamine levels were 6.4%, 14.9%, and 254.1 mmol/dL, respectively. The median of these glycemic markers was lowest in people with no CKD and highest in people with very severe CKD.
In the overall study population, the association of HbA1c with fasting glucose was stronger (r = 0.60, RMSE = 0.82) than the association of glycated albumin and fructosamine with fasting glucose (r = 0.46 [RMSE = 1.75] and r = 0.48 [RMSE = 1.83], respectively; Table 2 ). The associations of HbA1c, glycated albumin, and fructosamine with fasting glucose differed slightly across CKD categories. The association between HbA1c and fasting glucose was strongest in those with no CKD (r = 0.65) and weakest in those with very severe CKD (r = 0.48). The RMSE was approximately 40% larger in the very severe CKD group compared with the no CKD group (RMSE = 1.01 vs RMSE = 0.71, respectively). This trend was also observed when comparing glycated albumin and fructosamine with fasting glucose. In contrast, when glycated albumin and fructosamine were compared with HbA1c, Spearman's rank correlation coefficients were similar across CKD categories and the RMSE was only moderately higher in people with very severe CKD compared with those in the no CKD group. Similar results were observed with CKD defined using eGFR only (see Table S1 ,), albuminuria only (Table S2) , and when excluding people with very low Anemia was defined using sex-specific cut-off points of hemoglobin 130 g/L for men and 120 g/L for women.
serum albumin (Table S3) . Scatterplots of HbA1c, glycated albumin, and fructosamine with fasting glucose or HbA1c with the Deming regression line according to CKD category are shown in Fig. 1 . In analyses assessing anemia within CKD status, the weakening in the association of HbA1c, glycated albumin, and fructosamine with fasting glucose was more pronounced in people with anemia than in people without anemia according to CKD category (Table 3) . Similar results were observed when stratifying by anemia status only. In analyses stratified by anemia status only, the associations between HbA1c and fasting glucose were strongest in people without anemia and weakest in people with moderate anemia (Table S4 ). The associations of glycated albumin and fructosamine with fasting glucose were different by anemia status, as indicated by the different Deming regression slopes. In analyses that compared glycated albumin and fructosamine with fasting glucose or HbA1c, lower Spearman's rank correlation coefficients were observed in people with moderate anemia compared with people without anemia, but the RMSEs were relatively preserved.
In sensitivity analyses, we did not observe major differences by antidiabetic medication use (Table S5) , race (Table S6) , or sex (Table S7 ). In analyses that stratified CKD categories by HbA1c, RMSE was highest in people with HbA1c >8%. In addition, the RMSE tended to increase with the severity of CKD, but the differences were very modest (Table S8) . These values are likely unstable and should be interpreted with caution given the limited sample size after the additional stratification by HbA1c, particularly in people with very severe CKD.
Discussion
In this cohort of older adults with diagnosed diabetes, CKD was common and anemia was prevalent across all CKD categories. In people with very severe CKD, HbA1c, glycated albumin, and fructosamine were all poorly correlated with fasting glucose. However, the associations of glycated albumin and fructosamine with HbA1c were relatively preserved across CKD (Table 2) . Note, CKD staging was done using the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines (http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf, accessed 26 October 2017) with estimated glomerular filtration rate and albumin: creatinine ratio, which were combined to define four CKD categories: no CKD; moderate CKD; severe CKD; very severe CKD. RMSE, root mean square error.
categories, regardless of anemia status. These findings suggest that HbA1c performs similarly to glycated albumin and fructosamine in people with CKD. In people with diabetes, HbA1c is the standard measure recommended for use for monitoring glycemic control, regardless of CKD status. 18, 19 The American Diabetes Association and the National Kidney Foundation Kidney Disease Outcomes Quality Initiative Clinical Guidelines state that HbA1c may be limited in the setting of CKD but that there is insufficient evidence to recommend the use of glycated albumin or fructosamine over HbA1c. 18, 19 There are a number of factors that can interfere with the measurement or interpretation of HbA1c. Factors associated with shortened erythrocyte survival or decreases in mean erythrocyte age may affect the interpretation of HbA1c because these factors reduce the time for the chemical reaction between hemoglobin and glucose. Using HbA1c is particularly problematic in the setting of dialysis because of the high prevalence of severe anemia potentially from blood loss (i.e. treatment-related phlebotomy), uremic-induced inhibitors of erythropoiesis, and shortened erythrocyte survival. 8 Concerns have also been raised about the performance of HbA1c as a measure of glycemic control in the setting of earlier stages of CKD because anemia is common in early stages of CKD. 20 Glycated albumin and fructosamine are glycated serum proteins that are attractive as alternatives to HbA1c because they are not affected by hemoglobinrelated factors or erythrocyte turnover. Glycated albumin and fructosamine are also vulnerable to conditions that alter their values independent of average glucose. Indeed, the interpretation of glycated albumin and fructosamine may be limited in the setting of CKD due to proteinuria and impaired protein homeostasis. 21 Previous studies that have examined the associations of HbA1c and glycated albumin with fasting glucose have shown weaker correlations in people on dialysis compared with those not on dialysis, and postulated that HbA1c underestimates glycemic control in participants with diabetes on dialysis. 8, 9 Because of the perceived superiority of glycated albumin over HbA1c in the setting of dialysis, some countries, including Japan and Korea, recommend using glycated albumin over HbA1c to monitor glycemic control in dialysis patients. 22 However, we found that HbA1c was consistently associated with glycated albumin and fructosamine across CKD categories, suggesting that, at least outside the setting of dialysis, all three biomarkers may be performing similarly as measures of hyperglycemia. Anemia is common in older adults and in people with diabetes, particularly in people with CKD, 23, 24 and is thought to pose major problems for the interpretation of HbA1c as a measure of hyperglycemia. Nonetheless, findings for the performance of HbA1c in the setting of anemia have been mixed and may be attributed to differences in the cause of anemia between populations. 25, 26 In the present study, the association between HbA1c and fasting glucose was strongest in people without anemia and weakest in people with anemia (Table S3 ). Regardless of anemia status, we observed poor associations of HbA1c, glycated albumin, and fructosamine with fasting glucose in people with severe or very severe CKD. In contrast, we observed consistently concordant associations of glycated albumin, fructosamine, and HbA1c with each other across CKD categories and anemia status. Glycated albumin, fructosamine, and HbA1c all reflect chronic (average) glucose exposure and, as measures of glycated proteins, are more biologically similar to each other than to fasting glucose. It is notable that Spearman's rank correlation was higher in people without anemia than in people with moderate anemia. This may be because the range of glycated albumin and fructosamine was wider in people with no anemia than in people with moderate anemia in our analytic sample.
There is a large body of literature demonstrating a strong link between HbA1c and clinical complications, including in people with CKD. [27] [28] [29] [30] [31] In randomized clinical trials, reducing HbA1c in people with CKD has been associated with fewer microvascular complications. 32, 33 There is a growing literature demonstrating the prognostic value of glycated albumin and fructosamine with clinical outcomes, [34] [35] [36] [37] but there have been few studies on the performance of these biomarkers in people with CKD. 10, 38, 39 There are presently no clinical trial data demonstrating the effectiveness of glycated albumin or fructosamine as glycemic targets in people with moderate CKD. The overwhelming body of evidence for monitoring glycemic control in CKD is derived from studies of HbA1c, which remains the gold standard measure of glycemic control regardless of CKD status.
The poor correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose may partially reflect difficulties in the interpretation of fasting glucose in this population. Fasting glucose has higher withinperson variability compared with the other three biomarkers. 40, 41 In our study population, 62% of the participants were on glucose-lowering medications, suggesting that a single fasting measure in this population may be discordant with measures of "usual" glycemic control. However, in analyses stratified for glucoselowering medication use, we observed similar results.
In CKD specifically, fasting glucose values may be affected by drug clearance and impaired gluconeogenesis. Thus, fasting glucose may be a problematic reference standard in the setting of CKD. In addition, a single measure of fasting glucose does not reflect postprandial hyperglycemia; HbA1c, glycated albumin, and fructosamine are all affected by non-fasting as well as fasting glucose concentrations.
The results reported herein should be interpreted in the context of our study limitations. We cannot definitively determine which biomarker is "best" for monitoring glycemic control in the setting of CKD in the absence of a true gold standard measure of hyperglycemia. An additional limitation of the present study was the limited sample size of people with severe or very severe CKD, reflecting the community-based study population.
Strengths of the present study included the ability to conduct head-to-head comparisons of multiple glycemic markers in the setting of a diverse community-based study population of older adults with diabetes. In addition, CKD status was rigorously characterized with the availability of creatinine, cystatin C, and urine albumin and creatinine.
In our cohort of community-based participants with diagnosed diabetes, HbA1c, glycated albumin, and fructosamine were inconsistently associated with fasting glucose in people with severe to very severe CKD. However, glycated albumin and fructosamine were similarly associated with HbA1c across CKD categories, regardless of anemia status. Our results in an older population suggest that glycated albumin and fructosamine have similar performance to HbA1c and may not necessarily overcome limitations of HbA1c in people with CKD. Future studies with prospective follow-up for clinical outcomes are needed to help determine the best biomarker for glycemic control in older adults with diabetes and CKD. The use of continuous blood glucose monitors to estimate average glucose also has potential for helping address these questions because direct measures of circulating average glucose could provide a better reference standard. In the context of the current evidence, the present study supports the American Diabetes Association 19 and Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines 18 and suggests that it is premature to recommend glycated albumin or fructosamine over HbA1c as measures of glucose control in adults with moderate to severe CKD.
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